Akums Drugs & Pharmaceuticals Ltd. announced its Q2 FY26 results, showcasing international expansion and a 7% y-o-y volume increase in its CDMO segment. Revenue from the CDMO segment was ₹804 crore. The Hon’ble President of Zambia broke ground on a new pharmaceutical plant. The company also achieved its first commercial supply of formulations in Europe. Consolidated revenue stood at ₹1,018 crore.
Financial Performance in Q2 FY26
Akums Drugs & Pharmaceuticals Ltd. reported a consolidated revenue of ₹1,018 crore for the quarter ended September 30, 2025 (Q2 FY26), compared to ₹1,033 crore in Q2 FY25. EBITDA stood at ₹94 crore with a margin of 9.3%, and PAT was ₹43 crore.
CDMO Segment Growth
The Contract Development and Manufacturing Organizations (CDMO) segment remained a key contributor, generating revenue of ₹804 crore. Volumes for this segment grew by 7% year-over-year, contrasting muted industry volume growth.
Branded Formulations Performance
The domestic Branded Formulations business reported revenue of ₹122 crore with EBITDA margins improving to 21.6%. The Branded Export segment maintained a healthy EBITDA margin of 24.5%, despite seasonal impacts.
International Expansion
The Hon’ble President of Zambia recently initiated the groundbreaking of a new pharmaceutical plant, marking a joint venture between Akums and the Zambian government. This facility aims to improve access to quality medicines across SADC countries. Additionally, Akums achieved its first commercial supply of formulations in Europe, supplying Dapagliflozin tablets to Switzerland. Rivaroxaban tablet supply to Europe is expected in Q3.
H1 FY26 Performance
For the first half of FY26, revenue stood at ₹2,042 crore, with an EBITDA of ₹223 crore (margin of 10.9%) and a PAT of ₹107 crore.
Source: BSE
